TFRC and neoplasm: ↓ p53, EGFR, Ki-67↓ tumor vascularization- no change in transferrin receptor expression- remission to allow for hysterectomy – 1 patient- median remission – 6months- 6 patients relapsed- 4 out of 6 patients – enrolled in 2nd 28-day treatment cycle →2nd remission- 2 out 6 patients – opted out of 2nd 28-day treatment cycle →death after 12 and 13 months- Safe and well tolerated with no major adverse reactions→Artenimol-R improved clinical symptoms and was demonstrated to be safe and well-tolerated